HOME >> BIOLOGY >> NEWS
48-wk resistance data comparing GW433908 boosted & unboosted with nelfinavir

Boston (Feb. 11, 2003) Forty-eight-week data were presented here today from two Phase III studies (NEAT and SOLO) of treatment-nave patients with HIV infection, evaluating the resistance profile of the investigational protease inhibitor (PI) GW433908 (908) dosed twice a day (BID) or 908 boosted with the PI ritonavir (908/r) dosed once a day (QD) compared to the PI nelfinavir (NFV) BID. The medications in both studies were administered as part of combination therapy that also included 300 mg abacavir (ABC) BID and 150 mg lamivudine (3TC) BID. ABC and 3TC are nucleoside reverse transcriptase inhibitors (NRTIs).

908 is the calcium phosphate ester pro-drug of amprenavir (APV) and was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (Nasdaq: VRTX). In the SOLO study, no patients (0 percent) in the 908/r arm, out of 32 subjects experiencing virologic failure or with ongoing viral replication, had detectable primary or secondary PI mutations. In contrast, 27 of 54 patients (50 percent) in the NFV arm developed primary or secondary PI mutations. The clinical relevance of the resistance data is currently under evaluation.

In the NEAT study, 5 of 29 patients (17 percent) who experienced treatment failure in the unboosted 908 arm had mutations characteristic of APV resistance. NFV-selected mutations were observed in 7 of 26 patients (27 percent) who experienced virologic failure in the nelfinavir arm.

In the NEAT study, mutations selected by 908 were consistent with the spectrum of mutations selected by APV. Mutations detected in patients taking unboosted 908 included I54L/M, M46I and V32I+I47V. Mutations observed with other PIs (D30N, I54V, V82A/T/S, L90M) were not detected among patients taking unboosted 908.

In the SOLO study, there was a statistically significant difference between 908/r QD and NFV BID in the incidence of treatment emergent mutations selected by either the study PI (P<0.001) or the NRTIs ABC and
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
11-Feb-2003


Page: 1 2 3

Related biology news :

1. Master of antimalarial resistance
2. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
3. Evolvability could be a driving force in drug resistance
4. Insecticide resistance: A constraint on evolutionary change
5. New drug shows promise against Gleevec resistance in mice
6. New milestones on the path to conquering HIV drug resistance (AIDS)
7. Study investigates breast cancer resistance to tamoxifen and possible way to reverse it
8. Antibiotic resistance risk from triclosan questioned
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Researchers string together players in pesticide resistance orchestra
11. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: resistance data comparing boosted unboosted with nelfinavir

(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/29/2015)... 2015  Caris Life Sciences® today announced the ... researchers utilized Caris Molecular Intelligence®, the company,s panomic, ... targets in patients with colorectal and pancreatic cancer ... death protein 1 (PD-1) and its ligand, PD-L1. ... 2015 American Society of Clinical Oncology Annual Meeting ...
(Date:5/29/2015)... TRIANGLE PARK, N.C. , May 29, 2015 ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer ... the company,s business at the Jefferies 2015 Global Healthcare Conference ... The presentation and the immediately following Q&A session will take ... Time, and can be accessed via a live webcast on ...
(Date:5/29/2015)... Translation is frequently listed as one of ... reason--if used in a way that is right for a ... business product or service offering. , Here are some ... effect on a company's bottom line: , 1.    Attract bigger audience. ... world can use, why not offer it globally? Nelson Mandela ...
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated (NYSE: ... information services, announced that it is scheduled to speak ... York.  Steve Rusckowski , the company,s President and ... point strategy.  The presentation is scheduled for Tuesday, June ... The presentation will be webcast live during the conference ...
Breaking Biology Technology:Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Three Ways Translation Can Help Businesses Grow 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2
Cached News: